Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 14/20 | 0.59 |
| ▸ | FDPS | P14324 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1300120 | 0.95 | FDPS (0.67) | HPGDFDPSMAPTLMNAHTT | |
| SCHEMBL1299648 | 0.88 | HPGD (0.66) | HPGDFDPSMAPTNPSR1ALDH1A1 | |
| SCHEMBL9733843 | 0.86 | ALDH1A1 (0.57) | HPGDFDPSMAPTLMNAHTT | |
| SCHEMBL6584909 | 0.85 | ALDH1A1 (0.58) | HPGDFDPSMAPTLMNAHTT | |
| SCHEMBL14835808 | 0.84 | HPGD (0.54) | HPGDFDPSALDH1A1 | |
| SCHEMBL6584890 | 0.83 | ALDH1A1 (0.60) | HPGDFDPSMAPTLMNAHTT | |
| SCHEMBL1299029 | 0.83 | HPGD (0.65) | HPGDFDPS | |
| SCHEMBL1299795 | 0.83 | HPGD (0.65) | HPGDFDPSALDH1A1 | |
| SCHEMBL7914517 | 0.82 | FDPS (0.56) | HPGDFDPSMAPTLMNAHTT | |
| SCHEMBL5215062 | 0.82 | C5AR1 (0.57) | HPGDFDPSLMNASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2383263-B1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | UNIV CHOSUN IACF (KR) | 2014-04-16 | — | — | EP | disclosed |
| US-8637558-B2 | Thiazolidinedione derivative and use thereof | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2014-01-28 | — | — | US | disclosed |
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, CHOSUN UNIVERSITY (KR) | 2011-11-03 | — | — | US | disclosed |
| EP-2383263-A2 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | Industry-academic Cooperation Foundation, Chosun University (KR) | 2011-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269954-A1 | NOVEL THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF | HPGD, CYP27B1, GCDH | HPGD 1/4885FDPS 1287/4885MAPT 4513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.